Klotho Neurosciences(NASDAQ) KLTOW

Market CapN/A

Since IPO (2022)+11%

5 YearN/A

1 Year-27%

1 Month-19%

$0.16

+0%

+0.00Today

Klotho Neurosciences last closing stock price
Metric	Price	Date
Last close	USD 0.16	2026-07-27

Klotho Neurosciences stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-14.32%	USD 0.18	2026-07-20
1 month	-19.48%	USD 0.19	2026-06-26
3 month	-19.44%	USD 0.19	2026-04-28
Year to date	+61.63%	USD 0.10	2025-12-31
1 year	-26.54%	USD 0.21	2025-07-25
3 year	+170.51%	USD 0.06	2023-07-26
Since inception	+10.71%	USD 0.14	2022-04-29

Klotho Neurosciences Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$22.17M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.54 (Low)

Dividend

$0.00

Beta (Volatility)

0.54 (Low)

Price

$0.16

Volume

10,070

Open

$0.16

Price

$0.16

Volume

10,070

Open

$0.16

Previous Close

$0.16

Daily Range

$0.15 - $0.16

52-Week Range

$0.06 - $0.38

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

0.54 (Low)

Price

$0.16

Volume

10,070

Open

$0.16

Previous Close

$0.16

Daily Range

$0.15 - $0.16

52-Week Range

$0.06 - $0.38

Estimated Earnings Date

N/A

KLTOW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Klotho Neurosciences

Klotho Neurosciences, Inc. is a biopharmaceutical company dedicated to developing innovative medical treatments for severe illnesses, including cancer and neurological disorders. The company focuses on gene therapy candidates, particularly AMI-101 for Alzheimer's disease and AMI-202 for amyotrophic lateral sclerosis (ALS).

Products and Services

Gene therapy candidate AMI-101 for Alzheimer's disease
Gene therapy candidate AMI-202 for ALS management
Research and development of treatments for various severe illnesses

Growth Outlook

Significant market potential in neurodegenerative disease treatments
Ongoing clinical trials expected to yield promising results
Strategic partnerships may enhance research capabilities and funding

Financial Highlights

Recent quarterly net income of -$13.86 million
Cash and cash equivalents of $10 million as of March 2026
Current ratio of 19.74 indicates strong liquidity position

Klotho Neurosciences, Inc. is positioned in a rapidly evolving biotechnology sector, focusing on critical health challenges. The company's innovative gene therapy candidates aim to address significant unmet medical needs, particularly in neurodegenerative diseases. With a strong liquidity position, as evidenced by a current ratio of 19.74, Klotho Neurosciences is well-equipped to support its ongoing research and development efforts. The recent quarterly financials indicate a commitment to advancing its product pipeline, despite reporting a net loss. The potential for strategic partnerships and the promising market for neurodegenerative treatments further enhance the company's growth outlook.

AI Generated • Jul 19, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Omaha, NE 68144, US

KLTOW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-108.82%

Return on Capital

-75.51%

Return on Assets

-37.12%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

10.07K

Avg. Volume

24.05K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$15.07M

EBITDA

-$19.41M

Operating Cash Flow

-$9.31M

Capital Expenditure

-$365.32K

Free Cash Flow

-$9.67M

Cash & ST Invst.

$10.00M

Total Debt

$294.54K

Klotho Neurosciences Performance Analysis

Klotho Neurosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Klotho Neurosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-47.8%
Q3	2025-09-30	59.4%
Q4	2025-12-31	62.4%
Q1	2026-03-31	-719.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$13.86M

-520.3%

EBITDA

-$13.86M

-773.1%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$10.00M

+1667.6%

Total Debt

$294.54K

-83.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$294.54K

-83.3%

Return on Assets

-37.12%

N/A

Return on Invested Capital

-25.47%

N/A

Free Cash Flow

-$5.34M

-250.4%

Operating Cash Flow

-$4.97M

-226.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MDCXMedicus Pharma Ltd. Common Stock

MDCXMedicus Pharma Ltd. Common Stock$0.32-14.00%

IPSCCentury Therapeutics, Inc.

IPSCCentury Therapeutics, Inc.$2.09-0.95%

INMBINmune Bio, Inc.

INMBINmune Bio, Inc.$1.73+6.79%

EVAXEvaxion Biotech A/S

EVAXEvaxion Biotech A/S$2.89-2.36%

LTRNLantern Pharma Inc.

LTRNLantern Pharma Inc.$2.79+1.45%

JUNSJupiter Neurosciences, Inc.

JUNSJupiter Neurosciences, Inc.$0.11-6.20%

SKYESkye Bioscience, Inc.

SKYESkye Bioscience, Inc.$0.62-4.46%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$91.67-0.01%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.25+0.10%

NOKNokia

NOKNokia$9.28+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.95+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.24-0.02%

TAT&T

TAT&T$24.42+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.40-0.01%

Questions About KLTOW

What is the current price of Klotho Neurosciences?

Klotho Neurosciences is trading at $0.16 per share.

What is the 52-week range for Klotho Neurosciences?

Over the past 52 weeks, Klotho Neurosciences has traded between $0.06 and $0.38.

How much debt does Klotho Neurosciences have?

Klotho Neurosciences total debt is unavailable.

How much cash does Klotho Neurosciences have on hand?

Klotho Neurosciences does not have cash on hand data available.

What is Klotho Neurosciences’s dividend yield?

Klotho Neurosciences does not currently have a dividend yield.

Klotho Neurosciences(NASDAQ) KLTOW

Klotho Neurosciences Financials at a Glance

KLTOW News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Klotho Neurosciences

KLTOW Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Klotho Neurosciences Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About KLTOW

What is the current price of Klotho Neurosciences?

What is the 52-week range for Klotho Neurosciences?

How much debt does Klotho Neurosciences have?

How much cash does Klotho Neurosciences have on hand?

What is Klotho Neurosciences’s dividend yield?

Premium Investing Services